Trial Profile
Efficacy of lapatinib after pertuzumab and ado-trastuzumab emtansine in patients with metastatic HER2-positive breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2019
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Pertuzumab; Trastuzumab; Trastuzumab emtansine
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Feb 2017 New trial record